Amylyx Pharmaceuticals (AMLX) Net Income towards Common Stockholders (2021 - 2026)

Amylyx Pharmaceuticals' Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at -$41.2 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 14.77% year-over-year to -$41.2 million; the TTM figure through Mar 2026 stood at -$5.5 million (up 97.5% YoY), while the FY2025 annual figure was -$158000.0, up 99.95% from the prior year.
• Net Income towards Common Stockholders was -$41.2 million for Q1 2026 at Amylyx Pharmaceuticals, down from $111.6 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $111.6 million in Q4 2025 to a low of -$118.8 million in Q1 2024.
• Historically, Net Income towards Common Stockholders has averaged -$29.0 million across 5 years, with a median of -$41.2 million in 2026.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders plunged 7652.0% in 2024, then soared 402.03% in 2025.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$42.7 million in 2022, then surged by 106.32% to $2.7 million in 2023, then sank by 1469.78% to -$36.9 million in 2024, then jumped by 402.03% to $111.6 million in 2025, then sank by 136.93% to -$41.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$41.2 million (Q1 2026), $111.6 million (Q4 2025), and -$34.4 million (Q3 2025), per Business Quant data.